Enjoy complimentary customisation on priority with our Enterprise License!
The stem cell umbilical cord blood (UCB) market share is expected to increase by $1.47 bn from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 16.87%.
This stem cell umbilical cord blood (UCB) market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers stem cell umbilical cord blood market segmentations by end-user (pharmaceutical, research institutes, hospitals, and biobanks) and geography (North America, Asia, Europe, and Rest of World (ROW)). The stem cell umbilical cord blood (UCB) market report also offers information on several market vendors, including Americord Registry LLC, Athersys Inc., CBR Systems Inc., Cells4Life Group LLP, Celularity Inc., Cordlife Group Ltd., Cryo Cell International Inc., Cryo Stemcell, Cryoviva Biotech Pvt. Ltd., FamiCord Group, FUTURE CELL JAPAN, Global Cord Blood Corp., LifeCell International Pvt. Ltd., MEDIPOST Co. Ltd., Next Biosciences Pty Ltd., Regrow Biosciences Pvt Ltd., Smart Cells International Ltd., Smith and Nephew plc, ViaCord LLC, and Vita 34 International AG among others.
Download Report Sample to Unlock the Stem Cell Umbilical Cord Blood Market Size for the Forecast Period and Other Important Statistics
The rising prevalence of several chronic disorders is notably driving the stem cell umbilical cord blood (UCB) market growth, although factors such as the rising case of GVHD may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the stem cell umbilical cord blood (UCB) industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Stem Cell Umbilical Cord Blood (UCB) Market Driver
The rising prevalence of several chronic disorders is one of the major drivers of the stem cell UCB market growth. Chronic diseases are one of the major causes of disability and death globally. Four major chronic diseases are cardiovascular disease (CVD), cancer, chronic obstructive pulmonary disease, and type 2 diabetes, which occur due to high blood pressure, high blood cholesterol, overweight, physical inactivity, unhealthy diet, and use of tobacco. Globally, changing lifestyles increase the rates of these diseases in all socioeconomic classes. By 2022, chronic diseases are expected to rise to 72.94% of all deaths and 59.96% of the global burden of diseases. However, 78.92% of deaths related to these diseases occur in developing countries. Chronic diseases such as asthma, heart disease, cancers, and diabetes are usually incurable illnesses or conditions. These diseases are prevented through exercise, improved diet, and early detection. These diseases result in increased demand for stem cells against novel diseases, which in turn will drive the growth of the global stem cell UCB market during the forecast period.
Key Stem Cell Umbilical Cord Blood (UCB) Market Trend
Increasing awareness, associated research, and potential clinical applications for stem cell is one of the major trends of the stem cell UCB market growth. Key players in the iPSC generation industry are focusing on mergers and acquisitions (M and A) to increase their market share. For instance, in March 2021, Axol Biosciences signed a merger agreement with Censo Biotechnology. This entity is set to become one of the leading providers of products and services in the iPSC-based immune cell, neuroscience, and cardiac modeling for the drug discovery and screening segment. Moreover, the increasing awareness about stem cells and associated research, potential clinical applications, and rising financial assistance by governments and private vendors are expected to contribute to the growth of global stem cell UCB market during the forecast period.
Key Stem Cell Umbilical Cord Blood (UCB) Market Challenge
The rising case of GvHD is one of the major trends of the stem cell UCB market growth. The incidence rate of a GvHD globally is 40%, but the value varies from patient to patient, ranging from 10% to 80% in certain cases. On the other hand, the incidence rate of cGvHD is 50% in patients who underwent HSCT from an identical sibling. To date, no intervention can prevent the occurrence of GvHD. The treatment of GvHD involves medication therapy and T-cell depletion therapy. To overcome this challenge, vendors must develop novel drugs that mitigate the risk of developing GvHD to reduce the health burden as well as the economic burden of patients. These factors will negatively impact the growth of the global stem cell UCB market during the forecast period.
This stem cell umbilical cord blood (UCB) market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global antidepressant drugs market as a part of the pharmaceutical market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the stem cell umbilical cord blood (UCB) market during the forecast period.
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
This statistical study of the stem cell umbilical cord blood (UCB) market encompasses successful business strategies deployed by the key vendors. The stem cell umbilical cord blood (UCB) market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The stem cell umbilical cord blood (UCB) market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the leading companies' production, sustainability, and prospects.
Our report provides extensive information on the value chain analysis for the stem cell umbilical cord blood (UCB) market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
42% of the market’s growth will originate from North America during the forecast period. The US is the key market for stem cell umbilical cord blood (UCB) market in North America. Market growth in this region will be faster than the growth of the market in other regions.
The increasing presence of established vendors will facilitate the stem cell umbilical cord blood (UCB) market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The outbreak of COVID-19 in 2020 affected all countries in North America, particularly the US. The pandemic negatively impacted clinical trials and donors for stem cells in North America. A rise in the number of COVID-19 cases in the first quarter of 2020 led to the imposition of partial lockdowns in several countries, including Canada and Mexico. Thus, various non-urgent pharmaceutical operations, such as analytical testing, which could be halted or postponed, were either conducted in a limited capacity or closed as per the set guidelines.
To gain further insights on the market contribution of various segments Request PDF Sample
The stem cell umbilical cord blood (UCB) market share growth in the pharmaceuticals segment will be significant during the forecast period. The presence of a well-developed healthcare system allows pharmaceutical companies to provide biotechnology solutions such as stem cell UCB to easily establish themselves in the global stem cell UCB market.
This report provides an accurate prediction of the contribution of all the segments to the growth of the stem cell umbilical cord blood (UCB) market size and actionable market insights on the post-COVID-19 impact on each segment.
|
Stem Cell Umbilical Cord Blood (UCB) Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 16.87% |
|
Market growth 2022-2026 |
$1.47 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
16.1 |
|
Regional analysis |
North America, Asia, Europe, and Rest of World (ROW) |
|
Performing market contribution |
North America at 42% |
|
Key consumer countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
Americord Registry LLC, Athersys Inc., CBR Systems Inc., Cells4Life Group LLP, Celularity Inc., Cordlife Group Ltd., Cryo Cell International Inc., Cryo Stemcell, Cryoviva Biotech Pvt. Ltd., FamiCord Group, FUTURE CELL JAPAN, Global Cord Blood Corp., LifeCell International Pvt. Ltd., MEDIPOST Co. Ltd., Next Biosciences Pty Ltd., Regrow Biosciences Pvt Ltd., Smart Cells International Ltd., Smith and Nephew plc, ViaCord LLC, and Vita 34 International AG |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by End-user
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.